Lupin share was trading almost 2 percent at Rs 752 on January 9 as it got approval from the United States Food and Drug Administration (USFDA) to market generic bladder drug fesoterodine fumarate extended-release tablets 4 mg and 8 mg.
The product, a generic alternative of Pfizer’s Toviaz, will be used to treat overactive bladder (OAB) in adults with symptoms of urinary incontinence, urgency and frequency.
The company will manufacture the drug at its facility in Goa, India.
Follow our live blog for market action
As per IQVIA, fesoterodine fumarate had an estimated annual market size of $177 million as of September 2022.
The company released a few other products, including first of its kind triple drug combination on January 5 for treating inadequately controlled asthma.
It also received approval in December 2022 for the generic version of Brivaracetam tablets which is used to control partial onset seizures. As per IQVIA MAT, Brivaracetam tablets had estimated annual sales of $420 million in the US as of September 2022.
On the diagnostic front, Lupin has been expanding its presence, especially in central India. It launched its Regional Reference Laboratory in Indore, Madhya Pradesh in December and operates more than 325 LupiMitra (Lupin’s franchise collection centers) and 23 laboratories in India, the pharma firm has said.
At 11.27 am, Lupin was trading at Rs 751.95, 1.9 percent, on the National Stock Exchange.
Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
